论文部分内容阅读
目的 探讨影响肺癌预后的重要因素。方法 对 10 91例原发性肺癌病例 ,分析年龄、临床分期、病理类型和不同疗法等对预后的影响 ,用乘积限法 (productlimit)计算生存率 ,用对数秩和检验 (logranktest)其显著性。 结果 本组肺癌总的 1、3、5年生存率分别为 2 9.6 %、9.4%、5 .0 %。不同年龄组 5年生存率 :40～ 5 0岁 7.3 % ,高于其它各年龄组 (P <0 .0 1)。不同病理类型 5年生存率 :鳞癌 13 .2 % ,腺癌 9.5 % ,小细胞癌最差为 0 (P <0 .0 5 )。不同临床TNM分期 5年生存率 :Ⅰ～Ⅲa期分别为 17.0 %、9.5 %、1.9% ,Ⅲb和Ⅳ期均为 0 (P <0 .0 5 )。不同治疗方法 5年生存率 :手术治疗为 18.1% ,非手术治疗为 0 .0 2 % ;手术治疗中不同手术术式肺叶切除 2 5 .7% ,全肺切除 10 .8% (P <0 .0 5 ) ,且单纯手术治疗 2 2 .1% ,高于手术加综合治疗 ,但无显著性差异 (P >0 .0 5 ) ;非手术治疗中放疗加化疗为 2 .4% ,其它治疗均为 0 (P <0 .0 5 )。结论 年龄、病理类型、临床分期、不同治疗方法是影响预后的重要因素。
Objective To explore the important factors affecting the prognosis of lung cancer. Methods The effects of age, clinical stage, pathological type, and different therapies on the prognosis of 10 91 cases of primary lung cancer were analyzed. The survival rate was calculated by product limit, and it was significant by the log rank test. Sex. Results The overall 1-, 3-, and 5-year survival rates of lung cancer in this group were 29.6 %, 9.4%, and 5.0 %. The 5-year survival rate in different age groups: 7.3% in 40-50 years old, higher than other age groups (P < 0.01). The 5-year survival rate of different pathological types: squamous cell carcinoma 13.2%, adenocarcinoma 9.5%, and small cell carcinoma worst 0 (P < 0.05). The 5-year survival rates of different clinical TNM stages were 17.0%, 9.5%, and 1.9% in stage I to IIIa, respectively, and 0 (levels 0 and 0) in stages IIIb and IV (P < 0.05). The 5-year survival rate of different treatment methods was 18.1% for surgical treatment and 0. 02% for non-surgical treatment; 25.7% for different types of surgical lobectomy and 10.8% for pneumonectomy (P < 0). .0 5), and surgery alone was 22.1%, higher than surgery plus comprehensive treatment, but no significant difference (P> 0.05); non-surgical treatment plus radiotherapy and chemotherapy was 2.4%, other Treatments were all 0 (P < 0.05). Conclusion Age, pathological type, clinical stage, and different treatment methods are important factors affecting the prognosis.